Tamio Teramoto

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ^|^mdash;2012 Version

Tamio Teramoto, Junichi Sasaki, Shun Ishibashi et al. · Journal of Atherosclerosis and Thrombosis · 2013 · 469 citations · Full text

Medicine, Cardiology, Preventive Medicine +17

Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial

Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida et al. · American Journal of Kidney Diseases · 2018 · 384 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki et al. · The Lancet Diabetes & Endocrinology · 2017 · 309 citations

Medicine, Cardiology, Internal Medicine +13

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors

Yasuo Ikeda, Kazuyuki Shimada, Tamio Teramoto et al. · JAMA · 2014 · 305 citations

Medicine, Cardiology, Pharmacotherapy +17

Diagnostic Criteria for Dyslipidemia - Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Tamio Teramoto, Junichi Sasaki, Hirotsugu Ueshima et al. · Journal of Atherosclerosis and Thrombosis · 2007 · 229 citations · Full text

Medicine, Cardiology, Endocrinology +17